SIR-Spheres® Y-90 resin microspheres
Reimbursement
Under the terms of the Medicare Prescription Drug Improvement and Modernization Act (MMA) of 2003, Medicare, for the most part, reimburses hospitals for the cost of outpatient treatment with SIR-Spheres® Y-90 resin microspheres.
Many private payers also acknowledge the clinical utility of the SIRT procedure and have issued positive coverage policies for treatment.
Please see coding guides for more information:
*Reimbursement is a third-party determination process evaluated on a case-by-case basis and is not guaranteed by Sirtex.
Caution: Federal (USA) law restricts this device to sale by or on the order of a physician Indications for Use: SIR-Spheres® Y-90 resin microspheres are indicated for the local tumor control of unresectable hepatocellular carcinoma (HCC) in patients with no macrovascular invasion, Child Pugh-A cirrhosis, well-compensated liver function, and good performance status. They are also indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intra-hepatic artery chemotherapy (IHAC) of FUDR (Floxuridine). Side Effects: Common side effects are fever, transient decrease of hemoglobin, mild to moderate abnormality of liver function tests, abdominal pain, nausea, vomiting, and diarrhea. Potential serious effects due to exposure to high radiation include acute pancreatitis, radiation pneumonitis, acute gastritis, acute cholecystitis and radioembolization induced liver disease (REILD). Consult the Instructions for Use for a complete listing of indications, contraindications, side effects, warnings, and precautions.